Evogene Ltd. (EVGN)
Nasdaq · Healthcare · Biotechnology
$0.4038−4.99%as of Oct 6, 2026, 1:35 AM ET
- Market cap
- $6.4M
- 52-week range
- $0.35 – $1.50
- 52-week change
- −65.60%
- EPS (trailing)
- −$1.55
- Analyst rating
- 1.0 Strong buy
- Next earnings
- Nov 19, 2026
About Evogene Ltd.
Evogene Ltd., together with its subsidiaries, operates as a computational biology company in Israel, the United States, Europe, and Africa. It operates through three segments: Agriculture, Human Health, and Industrial Applications. The company engages in the agricultural activities, including seed traits and ag-chemicals activities; and design novel small molecules for drug development by utilizing ChemPass AI, a computational generative AI engine. It also focuses on the development and commercialization of castor bean seeds for industrial uses. In addition, the company medical cannabis products. It has a collaboration with LMU University Hospital Munich to develop novel therapies for hyper-inflammatory diseases driven by dysregulated neutrophil activity, including inflammatory bowel disease (IBD); and with ELEO, Inc. to develop oral small-molecule inhibitors targeting the PCSK9 pathway for the treatment of hyperlipidemia and cardiovascular diseases. The company was incorporated in 1999 and is headquartered in Rehovot, Israel.
Headquarters: Rehovot, Israel · 38 employees · evogene.com